Next 10 |
ImmunoGen is a promising turnaround equity that is approaching its inflection point in growth. Mirvetuximab is poised to gain approval toward yearend. In H2 this year, ImmunoGen is set to release a flurry of catalysts. For further details see: ImmunoGen: An Inflection Po...
Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a tradi...
Clovis Oncology is a highly volatile stock that rises and falls cyclically. Despite Rubraca's approval for two deadly cancer indications (ovarian and prostate), sales have been increasing modestly. Nevertheless, the latest ARIEL4 data positioned Rubraca to become the first-line dr...
It does mean that a company with research centered around each of these divisions, like a cluster of trees each growing additional branches from its own trunk, will usually do much better than a company working on a number of unrelated new products which, if successful, will land it in sev...
Deals and Financings Geneseeq, a Nanjing-Toronto company that offers genetic sequencing tests for cancer, completed a $114 million Series D financing led by China Reform Holdings Corporation (see story ). Geneseeq uses next-gen sequencing to provide decision-making tools for physicians. The...
Puma Biotechnology ( PBYI ) has been a very volatile biotech stock in the last several years: Data by YCharts Last year, we published two articles about Puma with expected growth in the company's stock, Puma Biotechnology: Risky Investment and Puma Biotechnology: Increasing Our Ex...
Editor's note: Seeking Alpha is proud to welcome Chen Yang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Editor's note: Seekin...
British pharma GlaxoSmithKline (NYSE: GSK) joined the recent groundswell of high-grade corporate bond issuers Monday to sell new debt. The UK-based firm priced US$3.5bn worth of ‘A’-rated, three-, five- and 10-year notes to help pay for its estimated US$5.1bn purchase of oncolo...
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
"A cynic is a man who, when he smells flowers, looks around for a coffin." - H.L. Mencken Stocks ended January on a high note with the major indices up just under one and half percent last week. It was the best start to a New Year since 1987 for investors after a dismal fourth quarter. T...